Peripheral T-Cell Lymphoma: Moving Toward Targeted Therapies

Samuel Y Ng; Eric D Jacobsen

doi:10.1016/j.hoc.2019.04.002

Peripheral T-Cell Lymphoma: Moving Toward Targeted Therapies

Hematol Oncol Clin North Am. 2019 Aug;33(4):657-668. doi: 10.1016/j.hoc.2019.04.002. Epub 2019 May 18.

Authors

Samuel Y Ng¹, Eric D Jacobsen²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: [email protected].
² Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

PMID: 31229161
DOI: 10.1016/j.hoc.2019.04.002

Abstract

Therapeutic advances for peripheral T-cell non-Hodgkin lymphoma (PTCL) have lagged behind their B-cell NHL counterparts in part because novel agents to treat PTCL have been developed empirically. The recent clinical success of brentuximab-vedotin suggests that novel therapies for PTCL can significantly improve outcomes when properly targeted. Aberrancies in T-cell receptor, Jak/STAT, and DNA methylation pathways play critical roles in T-NHL pathogenesis based on genomic studies and preclinical experimental validation. New strategies targeting these pathways in patients with PTCL are underway, and this clinical trial experience will possibly contribute to additional improvements in outcome for patients with these diseases.

Keywords: DNA methylation; Jak/STAT pathway; T-cell lymphoma; Targeted therapy.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Brentuximab Vedotin / therapeutic use*
Clinical Trials as Topic
Humans
Immunoconjugates / therapeutic use*
Immunotherapy
Lymphoma, T-Cell, Peripheral / genetics
Lymphoma, T-Cell, Peripheral / pathology
Lymphoma, T-Cell, Peripheral / therapy*
Molecular Targeted Therapy
Stem Cell Transplantation

Substances

Immunoconjugates
Brentuximab Vedotin